A Phase 1/2 interventional study of Linvoseltamab in Multiple Myeloma, sponsored by Regeneron Pharmaceuticals. Recruiting at 40 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by Regeneron Pharmaceuticals · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing linvoseltamab in Multiple Myeloma — 13 open to participants now, 15 under way, 4 of them phase 3. linvoseltamab · Multiple Myeloma.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, this one is the 4th largest by planned enrollment, is the only one that started in 2019, is one of 5 in phase 1/2, reaches primary completion later than 8 of the 14 other live ones, and was the 1st registered.
3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.
Browse Multiple Myeloma studies →13 of the 16 studies testing linvoseltamab in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States
Ages 18+
Regeneron Pharmaceuticals · Sites in United States, France, Japan and 3 more countries
Ages 18+
Multiple Myeloma Research Consortium · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18+
By country, each count listing its studies:
linvoseltamab: first FDA approval 2025 (LYNOZYFIC), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →
Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 2019; this study’s year is marked. 1 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 387 is above the median of 41 across 3,008 interventional studies indexed under Multiple Myeloma.
Median enrollment 168 across the 16 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
10 of 16 have an industry lead sponsor. The 6 most frequent:
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
15 studies in Multiple Myeloma by Regeneron Pharmaceuticals: 9 open now, 11 under way, 3 of them phase 3. Of 2 finished, 0 (0%) have results posted.
Among the 15 studies in Multiple Myeloma by Regeneron Pharmaceuticals, this one is the 3rd largest by planned enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2019, is one of 6 in phase 1/2, reaches primary completion later than 5 of the 10 other live ones, and was the 1st registered.
Regeneron Pharmaceuticals’s Multiple Myeloma studies by the year they started, since 2019.
2 of the studies testing linvoseltamab in Multiple Myeloma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06376526Dickran Kazandjian, MDIMMUNOPLANT for Newly Diagnosed Multiple Myeloma | 2027-08-31 |
| NCT07609940Regeneron PharmaceuticalsAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) | 2027-10-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies testing linvoseltamab in Multiple Myeloma, from their registry updates:
Among Regeneron Pharmaceuticals’s 15 in Multiple Myeloma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to learn about the safety of linvoseltamab and to find out what is the best dose of linvoseltamab to give to patients with multiple myeloma and to look for any signs that linvoseltamab can effectively treat cancer.
The study is looking at several other research questions, including:
Key Inclusion Criteria:
Patients must have myeloma that is response-evaluable according to the 2016 IMWG response criteria as defined in the protocol.
Phase 1, Part 1 (Dose Escalation): Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment disease or intolerance of the therapy and including either:
a. Progression on or after at least 3 , or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody, OR b. Progression on or after an anti-CD38 antibody and have disease that is "double refractory" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor (PI). Refractory disease is defined as lack of response or relapse within 60 days of last treatment.
Phase 1, Part 2 (SC Administration): Patients with MM whose disease meets the following criteria:
a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple-refractory, defined as being refractory to prior treatment with at least 1 anti-CD38 antibody, a proteasome inhibitor, and an IMiD.
Patients with MM whose disease meets the following criteria:
a. Progression on or after at least 3 prior lines of therapy including a(n) PI, IMiD, and anti-CD38 antibody, OR b. Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody.
Patients with MM whose disease meets the following criteria:
Patients must be triple- refractory, defined as being refractory* to prior treatment with at least 1 PI, 1 IMiD, and an anti-CD38 antibody.
AND, for ALL patients, if they have relapsed after a BCMA-directed CAR-T cellular therapy then:
Key Exclusion Criteria:
1. Diagnosis of plasma cell leukemia, primary systemic light-chain amyloidosis, (excluding myeloma-associated amyloidosis), Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes) 2. Patients with known MM brain lesions or meningeal involvement 3. Cardiac \<40% by echocardiogram or multi-gated acquisition scan (MUGA) 4. Prior treatment with BCMA-directed immunotherapies, including BCMA bispecific antibodies and BiTEs. Note: BCMA antibody-drug conjugates are not excluded and BCMA-directed CAR-T treatment is not excluded in Phase 2 Cohort 3.
5. History of stem cell transplantation at any time, or autologous stem cell transplantation within 12 weeks of the start of study treatment
Note: Other protocol defined inclusion / exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phase 1 has two parts. Part 1, consists of linvoseltamab intravenous (IV) dose escalation and Part 2, consists of subcutaneous (SC) administration.
Drug: Linvoseltamab
Low Dose of linvoseltamab IV monotherapy.
Drug: Linvoseltamab
High Dose of linvoseltamab IV monotherapy.
Drug: Linvoseltamab
Anti-interleukin (IL)-6 receptor (R) prophylactic therapy followed by high dose of IV linvoseltamab monotherapy.
Drug: Linvoseltamab
Administered per the protocol
Also known as: REGN5458, Lynozyfic™
Incidence of dose-limiting toxicities (DLTs) from the first dose through the end of the DLT observation period
Phase 1 and Phase 2 for Japanese cohort only
Time frame: Up to 28 days
Incidence and severity of treatment-emergent adverse events (TEAEs)
Phase 1
Time frame: Up to 5 years
Incidence and severity of adverse events of special interest (AESI)
Phase 1
Time frame: Up to 5 years
Assessment of the pharmacokinetics (PK) of linvoseltamab
Phase 1 part 2
Time frame: Up to 5 years
Concentrations of linvoseltamab in serum over time
Phase 2, for Japanese cohort only
Time frame: Up to 5 years
Objective response rate (ORR) as determined by an Independent Review Committee (IRC)
Phase 2, cohorts 1 and 2
Time frame: Up to 5 years
Incidence and severity of cytokine release syndrome (CRS) with linvoseltamab
Phase 2, cohort 3
Time frame: Up to 5 years
ORR of IV linvoseltamab as assessed by investigator
Phase 2, cohort 3
Time frame: Up to 5 years
Concentrations of linvoseltamab in the serum over time
Phase 1 part 1 and Phase 2
Time frame: Up to 5 years
Incidence over time of anti-drug antibodies (ADAs) to linvoseltamab
Phase 1 and Phase 2
Time frame: Up to 5 years
Titer of anti-drug antibodies (ADAs) to linvoseltamab over time
Phase 1 and Phase 2
Time frame: Up to 5 years
Incidence of neutralizing antibodies (NAb) to linvoseltamab over time
Phase 1 and Phase 2
Time frame: Up to 5 years
Duration of response (DOR) as determined by an IRC, measured using the IMWG criteria
Phase 2, cohorts 1 and 2
Time frame: Up to 5 years
DOR as determined by an investigator, measured using the International Myeloma Working Group (IMWG) criteria
Phase 1 and Phase 2
Time frame: Up to 5 years
Progression-free survival (PFS) as determined by an IRC, measured using the IMWG criteria
Phase 2
Time frame: Up to 5 years
PFS as determined by an investigator, measured using the IMWG criteria
Phase 1 and Phase 2
Time frame: Up to 5 years
Rate of minimal residual disease (MRD) negative status, using the IMWG criteria
Phase 1
Time frame: Up to 5 years
Rate of MRD negative status
Phase 2
Time frame: Up to 5 years
Overall survival (OS)
Phase 1 and Phase 2
Time frame: Up to 5 years
ORR as measured as determined by blinded IRC, as measured using the IMWG criteria
Phase 1, part 1 dose level 7 (DL7)
Time frame: Up to 5 years
ORR as determined by the investigator, measured using the IMWG criteria
Phase 1 and Phase 2
Time frame: Up to 5 years
Effects of linvoseltamab on health-related quality of life (HRQoL) and patient-reported symptoms and functioning per European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
Phase 2 The EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including global health status/quality of life, functional Scales (physical, role, emotional, cognitive, and social), symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). Participants rate items on a 4-point scale, with 1 as "not at all" and 4 as "very much."
Time frame: Up to 5 years
Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per Quality of Life Questionnaire-Multiple Myeloma module 20 [QLQ-MY20])
Phase 2 The EORTC QLQ-MY20 is a self -administered instrument to assess QoL in persons with MM. This 20-item questionnaire measures the following domains: symptom scales, including disease symptoms (6 items) and symptoms related to side effects of treatment (10 items); function scale and future perspective (3 items); and body image (1 item). A high score represents a high level of symptoms or problems.
Time frame: Up to 5 years
Effects of linvoseltamab on HRQOL and patient-reported symptoms and functioning per EuroQoL-5 Dimension-3 Level Scale [EQ-5D-3L])
Phase 2 The EQ-5D-3L is a self-administered generic standardized health status measure, consisting of an EQ-5D descriptive system and an EQ visual analog scale. The EQ-5D-3L descriptive system assesses 5 dimensions of health: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a 3-level scale: no problems, some problems, and extreme problems. The EQ visual analog scale component is a vertical visual analog scale used by patients to rate their health.
Time frame: Up to 5 years
Change in patient-reported global health status/QoL per EORTC QLQ-C30
Phase 2
Time frame: Baseline up to Up to 5 years
Time to definitive deterioration in patient-reported global health status/QoL per EORTC QLQ-C30
Phase 2
Time frame: Up to 5 years
Effects of linvoseltamab on general health status per EQ-5D-3L
Phase 2
Time frame: Up to 5 years
Effects of linvoseltamab on patient-reported functions and symptoms per EORTC QLQ-C30
Phase 2
Time frame: Up to 5 years
Effects of linvoseltamab on patient-reported functions and symptoms per QLQ-MY20
Phase 2
Time frame: Up to 5 years
Incidence and severity of TEAEs with linvoseltamab
Phase 2
Time frame: Up to 5 years
Incidence and severity of AESIs with linvoseltamab
Phase 2
Time frame: Up to 5 years
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Plan to share: Yes — All IPD that underlie results in a publication.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan) that support the methods and findings reported in a manuscript. Individual de-identified participant data will be made available once the indication has been approved by a regulatory body, if there is participant consent and there is not a reasonable likelihood of participant re-identification.
Data sharing details ↗ · vivli.org
Started Jan 2019 (actual). Primary completion is estimated for Mar 2033, 170 months after the start.
Of 98 industry-sponsored phase 1/2 interventional studies under Multiple Myeloma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 90. This study's planned 170 months is above that.
Counting every sponsor, half of 201 studies reached it within 65 months; a quarter within 44 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Linvoseltamab